Survival and Prognostic Factors in Patients with Breast Cancer: Cohort Study

• Main Author: Costa, Rafael Everton Assunção Ribeiro da
• Publication Date: 2025
• Other Authors: Rodrigues, Samya Viana da Silva, Mendes, Ana Carolina Vieira, Costa, Rackell Ramos Everton, Sá, Marcela Coêlho de, Vieira, Sabas Carlos, Sá, Carlos Eduardo Coelho de, Valença, Rodrigo José de Vasconcelos
• Format: Article
• Language: por; eng; spa
• Source: Revista Brasileira de Cancerologia (Online)
• Download full: https://rbc.inca.gov.br/index.php/revista/article/view/4839
• topic: Prognóstico; Condições Patológicas Anatômicas; Avaliação dos Resultados dos Cuidados de Saúde/estatística & dados numéricos; Neoplasias da Mama/diagnóstico; Prognosis; Anatomical Pathological Conditions; Health Care Outcome Assessment/statistics & numerical data; Breast Neoplasms/diagnosis; Pronóstico; Condiciones Patológicas Anatómicas; Evaluación de Resultado en la Atención de Salud/estadística & datos numéricos; Neoplasias de la Mama/diagnóstico.

Introduction: Breast cancer is the most common cancer in the world and an important cause of death among women. Objective: To analyze survival and prognostic factors in a cohort of patients with breast cancer. Method: Retrospective cohort of 201 patients with breast cancer treated between January 2018 and December 2022 at a tertiary hospital in Caxias, Maranhão, Brazil. Data were collected between January and June 2023 and analyzed with software R, version 4.0.2. Overall survival (OS) and disease-free survival (DFS) curves were constructed using the Kaplan-Meier model. A descriptive analysis was performed by calculating absolute (n) and relative frequencies (%) and evaluating prognostic factors with Cox regression. Statistical significance was evaluated through the Wald Test, with a level of 5%. Results: The 5-year OS and DFS were 91.3% and 72.4%, respectively. Women predominated (98.5%) over 40 years of age (86.1%) and with invasive carcinoma of no-special type (94%), G1 or G2 (79.1%), smaller than 5 cm (64.6%), without angiolymphatic (52.7%) and neural (77.6%) invasion and luminal molecular subtype (65.2%). Males had higher risk of death. Patients with angiolymphatic and neural invasion and non-expression of estrogen receptors (ER) had higher risk of recurrence. Conclusion: The 5-year OS and DFS were 91.3% and 72.4%, respectively. Male gender, angiolymphatic and neural invasion and non-expression of ER were prognostic factors associated with higher risk of death or recurrence.